Acadia Pharmaceuticals Inc. (ACAD) stock analysis

ACAD · Acadia Pharmaceuticals Inc.

Latest recorded price: USD 18.67

Model-estimated fair value: USD 6.56. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $18.67, ACAD trades 184.6% above the model's base-case value of $6.56. Using FCFF DCF, the model estimates $6.32 in the conservative case and $6.95 in the optimistic case, with a valuation confidence score of 55/100. About 75% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 27.5%, free cash flow margin 9.8%, ROIC 33.0%. The model flags 1 risk signal for this company.

Similar companies in Healthcare